Evidence map›Paper›PMID 31695847›Full record

ArticleOncotarget2019

Correction: Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.

Giovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, Francesco Marampon, Roberta Sferra, Simona Pompili, Leda Assunta Biordi, Roberto Iorio, Vincenzo Flati, Christian Argueta and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Giovanni Luca GravinaDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.
Andrea ManciniDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.
Alessandro ColapietroDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.
Francesco MaramponDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.
Roberta SferraDepartment of Biotechnological and Applied Clinical Sciences, Division of Human Anatomy, University of L'Aquila, L'Aquila, Italy.
Simona PompiliDepartment of Biotechnological and Applied Clinical Sciences, Division of Human Anatomy, University of L'Aquila, L'Aquila, Italy.
Leda Assunta BiordiDepartment of Biotechnological and Applied Clinical Sciences, Division of Molecular Pathology, University of L'Aquila, L'Aquila, Italy.
Roberto IorioDepartment of Biotechnological and Applied Clinical Sciences, Division of Applied Biology, University of L'Aquila, L'Aquila, Italy.
Vincenzo FlatiDepartment of Biotechnological and Applied Clinical Sciences, Division of Molecular Pathology, University of L'Aquila, L'Aquila, Italy.
Christian ArguetaKaryopharm Therapeutics, Newton, MA, USA.
Yosef LandesmanKaryopharm Therapeutics, Newton, MA, USA.
Michael KauffmanKaryopharm Therapeutics, Newton, MA, USA.
Sharon ShachamKaryopharm Therapeutics, Newton, MA, USA.
Claudio FestucciaDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.18632/oncotarget.22760.].

Identifiers

PMID31695847
PMCPMC6824873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.